Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v2-FR
Language English French
Date Updated 2023-04-12 2022-12-12
Drug Identification Number 02324970 02324970
Brand name SANDOZ ATORVASTATIN SANDOZ ATORVASTATIN
Common or Proper name ATORVASTATIN ATORVASTATIN
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients ATORVASTATIN ATORVASTATIN
Strength(s) 80MG 80MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100FCT 100FCT
ATC code C10AA C10AA
ATC description LIPID MODIFYING AGENTS, PLAIN LIPID MODIFYING AGENTS, PLAIN
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2022-12-12 2022-12-12
Estimated end date 2023-04-28 2023-03-24
Actual end date 2023-04-11
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments